All Stories

  1. Focused Ultrasound for Brain Metastases
  2. Enhancing lung cancer screening through ‘saved by the scan’: insights from a multipronged public service advertising campaign
  3. 30-day postoperative mortality and the effects of hospital preparedness during the COVID-19 pandemic: a pooled analysis of prospective international cohort studies
  4. Tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2 positive breast cancer (TUTOR): Study protocol for a multicenter phase 1 clinical trial
  5. Applications of transcranial focused ultrasound for primary brain tumors
  6. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial
  7. NCOG-66. ‘Core outcome set’ for leptomeningeal disease (LeptoCOS): a multi-disciplinary, international, consensus effort
  8. SURG-98. Clinical outcomes, operational metrics, and translational insights derived from trials of MR-guided, transcranial, microbubble-enhanced focused ultrasound for brain tumors: a 2010-2025 evidence analysis
  9. BIOS-08. TREATMENT STRATEGIES FOR PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE (LMD): A NETWORK META-ANALYSIS (NMA) OF RANDOMIZED CONTROLLED TRIALS
  10. SURG-101. A pilot study of laser interstitial thermal therapy (LITT) followed by hypofractionated radiation therapy (hypoRT) for patients with recurrent gliomas
  11. Communicating uncertainty in evidence-to-decision translation in NASS Guidelines
  12. Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
  13. A nomogram to predict development of brain metastasis in non-small cell lung cancer patients: a retrospective analysis using routinely available medical records
  14. Acoustic emissions dose and spatial control of blood-brain barrier opening with focused ultrasound
  15. Correction: Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database
  16. Data from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
  17. Supplemental Figure 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
  18. Supplemental Figure 2 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
  19. Supplemental Figure 3 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
  20. Supplemental Table 1 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
  21. Supplemental Table 2 from A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy
  22. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
  23. DSAI-08 MACHINE LEARNING-BASED PREDICTION OF INPATIENT CARE COSTS FOR PATIENTS WITH BRAIN METASTASES: A CLAIMS-BASED ANALYSIS
  24. NCTQ-10 INPATIENT CARE COSTS AND ASSOCIATED REIMBURSEMENTS FOR PATIENTS WITH LEPTOMENINGEAL METASTATIC DISEASE: A REAL-WORLD CLAIMS-BASED ANALYSIS
  25. RMTD-03 SOCIOECONOMIC DISPARITIES IN CLINICAL TRIAL ENROLLMENT AMONG PATIENTS WITH BRAIN METASTASES: A CENTRAL PENNSYLVANIA CROSS-SECTIONAL ANALYSIS IN NEIGHBORHOOD-DISADVANTAGE METRICS
  26. RMTD-09 ‘CORE OUTCOME SET’ FOR LEPTOMENINGEAL DISEASE (LEPTOCOS): A MULTI-DISCIPLINARY, INTERNATIONAL, CONSENSUS EFFORT
  27. RMTD-10 THERAPIES FOR LEPTOMENINGEAL METASTATIC DISEASE: A NETWORK META-ANALYSIS
  28. RMTD-11 EVALUATING THE QUALITY OF CONDUCT AND REPORTING OF CLINICAL PRACTICE GUIDELINES IN CNS METASTASES
  29. Survival in Patients with Colorectal Cancer and Isolated Brain Metastases: Temporal Trends and Prognostic Factors from the National Cancer Database (2010–2020)
  30. Editorial: Towards 2030: sustainable development goal 3: good health and wellbeing. A sociological perspective
  31. A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy
  32. A multicenter, pivotal trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) for plasma-based liquid biopsy in patients with glioblastoma (LIBERATE).
  33. A multicenter, randomized, controlled, pivotal trial of microbubble-enhanced transcranial focused ultrasound for patients with NSCLC brain metastases (LIMITLESS).
  34. Multicenter trial of microbubble-enhanced transcranial focused ultrasound (MB-FUS) with monthly adjuvant temozolomide for patients with high-grade gliomas.
  35. Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020)
  36. Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
  37. Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database
  38. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Matched-Case-Control Study
  39. Acoustic Emissions Dose and Spatial Control of Blood-Brain Barrier Opening with Focused Ultrasound
  40. Leptomeningeal Disease
  41. Leptomeningeal metastatic disease: new frontiers and future directions
  42. Burden of disease scenarios by state in the USA, 2022–50: a forecasting analysis for the Global Burden of Disease Study 2021
  43. Effect of adequacy of empirical antibiotic therapy for hospital-acquired bloodstream infections on intensive care unit patient prognosis: a causal inference approach using data from the Eurobact2 study
  44. Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions
  45. BIOS-01. MACHINE LEARNING-BASED PREDICTION OF INPATIENT CARE COSTS FOR PATIENTS WITH BRAIN METASTASES: A REAL-WORLD ANALYSIS
  46. BIOS-04. THERAPIES FOR LEPTOMENINGEAL DISEASE: A NETWORK META-ANALYSIS
  47. CTNI-32. A MULTICENTER PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER2 POSITIVE BREAST CANCER (TUTOR)
  48. EPID-14. PATTERNS OF CARE AND PROGNOSTIC FACTORS FOR PATIENTS WITH BRAIN METASTASES FROM COLON CANCER: A REAL-WORLD STUDY
  49. EPID-15. INPATIENT CARE COSTS AND ASSOCIATED REIMBURSEMENTS FOR PATIENTS WITH LEPTOMENINGEAL DISEASE: A REAL-WORLD ANALYSIS
  50. EPID-17. REAL-WORLD OUTCOMES OF BRAIN METASTASES FROM PANCREATIC CANCER: AN ANALYSIS OF 1266 PATIENTS
  51. EPID-18. PATTERNS OF CARE AND CLINICAL OUTCOMES OF PATIENTS WITH GLIOBLASTOMA FROM 2005-2020: A REAL-WORLD ANALYSIS
  52. INNV-15. A PIVOTAL, MULTICENTER TRIAL OF FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR PLASMA-BASED LIQUID BIOPSY IN PATIENTS WITH GLIOBLASTOMA (LIBERATE)
  53. RTID-03. A MULTICENTER, RANDOMIZED, CONTROLLED TRIAL OF FOCUSED-ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER DISRUPTION PLUS SYSTEMIC PEMBROLIZUMAB FOR PATIENTS WITH NSCLC BRAIN METASTASES (LIMITLESS)
  54. RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
  55. Peer Review Report For: Development and Initial Implementation of a Clinical Monitoring Strategy in a Non-regulated Trial: a research note from the ReStOre II Trial [version 3; peer review: 3 approved]
  56. Advancing spine evidence synthesis: North American Spine Society (NASS) Guidelines
  57. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  58. P14.02.B A MULTICENTER, RANDOMIZED, CONTROLLED TRIAL OF FOCUSED-ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER DISRUPTION PLUS SYSTEMIC PEMBROLIZUMAB FOR PATIENTS WITH NSCLC BRAIN METASTASES (LIMITLESS)
  59. P14.05.A A PROSPECTIVE, MULTICENTER TRIAL OF FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  60. P10.19.A MACHINE LEARNING-BASED PREDICTION OF INPATIENT CARE COSTS FOR PATIENTS WITH BRAIN METASTASES: A REAL-WORLD ANALYSIS
  61. KS03.4.A PATTERNS OF CARE AND CLINICAL OUTCOMES OF PATIENTS WITH GLIOBLASTOMA IN THE UNITED STATES FROM 2005-2020: A REAL-WORLD ANALYSIS
  62. P17.15.A PATTERNS OF CARE AND OUTCOMES IN BRAIN METASTASES FROM BILIARY TRACT CANCERS IN THE UNITED STATES: A REAL-WORLD ANALYSIS
  63. P06.11.A TUTOR: A MULTICENTER, PHASE 1 TRIAL OF TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER
  64. Program Signaling and Geographic Preferences in the United States Residency Match for Neurosurgery
  65. 458P Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
  66. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  67. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  68. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  69. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  70. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  71. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  72. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  73. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  74. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  75. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  76. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  77. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  78. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  79. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  80. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  81. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  82. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  83. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  84. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  85. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  86. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  87. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  88. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  89. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  90. Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  91. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  92. Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  93. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  94. Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  95. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  96. Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  97. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  98. Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  99. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  100. Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  101. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  102. Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  103. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  104. Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  105. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  106. Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  107. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  108. Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  109. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  110. Supplementary Table S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  111. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  112. Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  113. Peer Review Report For: Development and Initial Implementation of a Clinical Monitoring Strategy in a Non-regulated Trial: a research note from the ReStOre II Trial [version 2; peer review: 2 approved, 1 approved with reservations]
  114. A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)
  115. Presentation, management, and outcomes of older compared to younger adults with hospital-acquired bloodstream infections in the intensive care unit: a multicenter cohort study
  116. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
  117. A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).
  118. Examining global and gender disparities in high-impact evidence synthesis on lung cancer: A 2000-2024 analysis of Cochrane Library.
  119. Impact of race and ethnicity on financial toxicity in patients with genitourinary cancers.
  120. Pulmonary contusion with hemoptysis from lacrosse ball strike: A case report
  121. A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR).
  122. A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).
  123. A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).
  124. CSF proteomics for predicting response to treatment in patients with primary and secondary central nervous system lymphoma.
  125. Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.
  126. Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.
  127. Ethnic disparities in biomarker testing of patients with metastatic NSCLC in the United States: A real-world analysis.
  128. Health state utility assessment for low-grade glioma.
  129. Socioeconomic disparities in survival outcomes of patients with SCLC with brain metastases: A nationwide analysis.
  130. Survival outcomes associated with treatment modalities in stage 4 gallbladder neuroendocrine tumors: A nationwide analysis.
  131. Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis.
  132. Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis.
  133. Burden of disease scenarios for 204 countries
  134. MP08-17 OUTCOMES OF INVASIVE PRIMARY URETHRAL CANCER IN WOMEN (IPUC): AN ANALYSIS FROM THE NATIONAL CANCER DATABASE
  135. Correction: The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
  136. 151 Exceptional Responders to Base Excision Repair (BER) Inhibition for Recurrent Glioblastoma Display Enrichment for DNA Damage Response Pathways: RNA Sequencing Analysis From a Multicenter Trial
  137. 501 Systemic Immunological Suppression in Glioblastoma Is Targeted by Concurrent VEGF and PD-1 Inhibition in a Dose-Dependent Manner: Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq) From a Randomized Controlled Trial
  138. Safety and Feasibility of JAK Inhibitor Ruxolitinib in Newly-Diagnosed High-Grade Gliomas (CRUX): Final Trial Report
  139. MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma
  140. The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections
  141. Disparities in Noninvasive Traditional and Advanced Testing for Coronary Artery Disease: Findings from the INCAPS-COVID 2 Study
  142. Outcomes of invasive primary urethral cancer in women: An analysis from the national cancer database
  143. Treatment strategies and survival outcomes in Non-invasive Primary Urethral Cancer (NPUC): A comprehensive analysis from a large database
  144. “Open-window” craniectomy for the removal of frontal sinus mucosa to prevent a delayed mucocele: illustrative case
  145. Symptomatic Cerebellar Ptosis following Cerebellar Hematoma Evacuation: A Case Report and Review of the Literature
  146. Treatment Strategies for Primary Cavernous Sinus Meningiomas: A Systematic Review and Meta-analysis
  147. Peer Review Report For: Invisibility in global health: A case for disturbing bioethical frameworks [version 2; peer review: 2 approved, 1 approved with reservations]
  148. Prophylactic Radiotherapy Of MInimally Symptomatic Spinal Disease (PROMISSeD): study protocol for a randomized controlled trial
  149. Financial barriers and inequity in medical education in India: challenges to training a diverse and representative healthcare workforce
  150. Correction
  151. Impact of tissue-agnostic approvals on management of primary brain tumors
  152. An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
  153. Management of Brain Metastases: A Review of Novel Therapies
  154. SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm
  155. Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries
  156. CTNI-08. TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
  157. CTNI-21. PHASE I STUDY OF BTK INHIBITOR IBRUTINIB WITH TEMOZOLOMIDE AND RADIATION IN NEWLY-DIAGNOSED GLIOBLASTOMA (EQUILIBRIUM): FINAL TRIAL REPORT
  158. CTNI-55. A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  159. DNAR-05. EXCEPTIONAL RESPONDERS TO BASE EXCISION REPAIR (BER) INHIBITION FOR RECURRENT GLIOBLASTOMA DISPLAY ENRICHMENT FOR DNA DAMAGE RESPONSE PATHWAYS: RNA SEQUENCING ANALYSIS FROM A MULTICENTER TRIAL
  160. IMMU-02. IS DUAL AGENT IMMUNOTHERAPY SHIFTING THE EPIDEMIOLOGY OF MELANOMA BRAIN METASTASES? A REAL-WORLD ANALYSIS AND SINGLE-INSTITUTION VALIDATION
  161. IMMU-34. SYSTEMIC IMMUNE SUPPRESSION IN GLIOBLASTOMA IS TARGETED BY CONCURRENT VEGF AND PD-1 INHIBITION IN A DOSE-DEPENDENT MANNER: TRANSCRIPTOMIC FINDINGS THROUGH CITE-SEQ FROM A RANDOMIZED CONTROLLED TRIAL
  162. RTID-01. A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)
  163. SURG-27. 17-YEAR EXPERIENCE OF SURGICAL MANAGEMENT OF INTRADURAL EXTRAMEDULLARY (IDEM) TUMORS: CLINICAL OUTCOMES FROM A LOW- AND MIDDLE-INCOME COUNTRY
  164. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients
  165. Management of Postoperative Discitis with Debridement and Novel Technique of Local Antibiotic Instillation: Functional Outcomes from a Resource-Limited Setting
  166. Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison
  167. Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
  168. P03.15.B SURGICALLY TARGETED RADIATION THERAPY (START) FOR RECURRENT GLIOBLASTOMA: INITIAL OUTCOMES FROM A PROSPECTIVE MULTICENTER REGISTRY
  169. P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
  170. P07.13.B A RANDOMIZED STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND FOR BLOOD-BRAIN BARRIER DISRUPTION FOR BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER (LIMITLESS)
  171. P14.11.B A MULTICENTER STUDY OF LOW-INTENSITY FOCUSED ULTRASOUND WITH SYSTEMIC MICROBUBBLE OSCILLATORS FOR BLOOD-BRAIN BARRIER DISRUPTION FOR LIQUID BIOPSY IN GLIOBLASTOMA (LIBERATE)
  172. JS06.5.A TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
  173. Neurosurgeon’s Ode to Meningiomas
  174. Authors' Response to Letter Regarding ‘The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators’ (Preprint)
  175. Authors' Reply to: Research Training For Medical Students To Stand Out In Residency Applications. Comment on "The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and ...
  176. Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
  177. Authorship diversity in global evidence synthesis in genitourinary oncology: A 1998-2022 analysis of cochrane reviews.
  178. Enhancing lung cancer screening through ‘Saved by the Scan’: Lessons from a multipronged public service advertising program.
  179. Low-intensity focused ultrasound with systemic microbubble oscillators for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE).
  180. Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report.
  181. Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report.
  182. Survival outcomes of micropapillary versus classic variant, loco-regional bladder cancer: A 2004-2019 National Cancer Database analysis.
  183. Survival outcomes of sarcomatoid versus classic urothelial carcinoma of bladder.
  184. Ethnic disparities in biomarker testing and targeted therapy use in metastatic lung adenocarcinoma: A 2014-2021 analysis.
  185. Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.
  186. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
  187. Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
  188. Authorship Diversity in Urology: 1998-2022 Cochrane Review Analysis
  189. Diploic Bone Channel Drilling Facilitates Dissection of the Midline Dura and Protects the Superior Sagittal Sinus in Hyperostosis Frontalis Interna
  190. SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM)
  191. DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
  192. Who coauthors Cochrane Reviews related to genitourinary cancers? A 1998-2022 analysis of country and gender diversity.
  193. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study
  194. Treatments for intracranial hypertension in acute brain-injured patients: grading, timing, and association with outcome. Data from the SYNAPSE-ICU study
  195. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators
  196. Monitoring committees in clinical trials
  197. Phases of clinical trials
  198. Correlation
  199. List of contributors
  200. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Case-Control Study
  201. Novel Therapeutic Approaches in Neoplastic Meningitis
  202. Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis
  203. Inequities in Country- and Gender-Based Authorship Representation in Cardiology-Related Cochrane Reviews
  204. Serum Thyroid-Stimulating Hormone and 25-Hydroxycholecalciferol Levels in Children with Autism Spectrum Disorder and Intellectual Disability in Northern India: A Case-Control Study (Preprint)
  205. The Future of Pulmonary Medicine Physician Work-Force in India
  206. Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries
  207. Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
  208. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis
  209. COVID-19-Associated Mucormycosis in a Tertiary Care Hospital in India: A Case Series
  210. Intracranial Pressure Monitoring in Patients With Spontaneous Intracerebral Hemorrhage
  211. Authorship Diversity in Cochrane Systematic Reviews of Stroke: Inequities in Global Representation (P18-2.002)
  212. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
  213. Rising Inequity and Disparities in Medical Education in India: Challenges to Training a Representative Workforce (Preprint)
  214. Advanced subspecialty cardiology training in India in 2022: challenges and future directions
  215. Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study
  216. COUNTRY AND GENDER DIVERSITY IN CARDIOLOGY-RELATED COCHRANE REVIEWS: INEQUITIES IN GLOBAL REPRESENTATION
  217. Total hip arthroplasty for failed osteosynthesis of proximal femoral fractures: Clinical outcomes from a low- and middle-income country
  218. Overseas Medical Students in Ukraine and War-Related Interruption in Education: Global Health Considerations from India
  219. Management of postoperative discitis with debridement and local antibiotic infusion: functional outcomes from a low-middle-income country
  220. Functional outcomes after modified Blair's procedure for ankle arthritis secondary to Hawkins type III talus injuries: A retrospective cohort study
  221. In Reply: Predictors of Academic Neurosurgical Career Trajectory Among International Medical Graduates Training Within the United States
  222. The perceived impact of the Covid-19 pandemic on medical student education and training – an international survey
  223. 2021 Scientific Session of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), Las Vegas, Nevada, 31 August–3 September 2021: Posters
  224. Educating the Next Generation of Global Neurosurgeons: Competencies, Skills, and Resources for Medical Students Interested in Global Neurosurgery
  225. Percutaneous image-guided cryoablation of spinal metastases: A systematic review
  226. Pediatric Brain Tumors: From Modern Classification System to Current Principles of Management
  227. BJS commission on surgery and perioperative care post-COVID-19
  228. Comparison of Blister Aneurysm Treatment Techniques: A Systematic Review and Meta-Analysis
  229. Impact of COVID-19 on Diagnostic Cardiac Procedural Volume in Oceania: The IAEA Non-Invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
  230. Learning to practice medicine during COVID-19 and mucormycosis epidemics: an intern perspective from India
  231. Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
  232. Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World
  233. Lessons from the life of Asia’s first female neurosurgeon for modern neurosurgical trainees and educators worldwide
  234. MP67-14 SCIENTIFIC AUTHORSHIP OF COCHRANE SYSTEMATIC REVIEWS IN UROLOGY: A 2020 ANALYSIS
  235. Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia
  236. State of Accredited Endovascular Neurosurgery Training in India in 2021: Challenges to Capacity Building in Subspecialty Neurosurgical Care
  237. The Perceived Impact of the Covid-19 Pandemic on Medical Student Education and Training – An International Survey
  238. SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
  239. Letter: Predictors of Academic Neurosurgical Career Trajectory Among International Medical Graduates Training Within the United States
  240. Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
  241. Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe
  242. Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!
  243. Anxiety, Uncertainty, and Resilience of Medical Students Worldwide during the COVID-19 Pandemic
  244. Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study
  245. Abstract 831: State of medical and surgical oncology training in India: An infrastructural challenge to delivering high-quality cancer care
  246. Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study
  247. Global Landscape of Glioblastoma Multiforme Management in the Stupp Protocol Era: Systematic Review Protocol
  248. Letter to the Editor Regarding “Characterizing the Effect of Pass/Fail U.S. Medical Licensing Examination Step 1 Scoring in Neurosurgery: Program Directors' Perspectives”
  249. The perceived global impact of the COVID‐19 pandemic on doctors’ medical and surgical training: An international survey
  250. Antibiotics for treatment of irritable bowel syndrome in adults
  251. Medical Students in Global Neurosurgery: Rationale and Role
  252. Retractions and Withdrawals in Neurology Literature: A 2020 Analysis of the Retraction Watch Database (2668)
  253. The perceived global impact of the COVID-19 pandemic on doctors’ medical and surgical training: an international survey
  254. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study
  255. Timing of surgery following SARS-CoV-2 infection
  256. Biographies of international women leaders in neurosurgery
  257. Decline of Empathy During Medical Education
  258. Decline of Empathy During Medical Education
  259. Delivering High-Quality, Equitable Care in India: An Ethically-Resilient Framework for Healthcare Innovation After COVID-19
  260. Letter by Ozair et al Regarding Article, “The Upcoming Epidemic of Heart Failure in South Asia”
  261. International Impact of COVID-19 on the Diagnosis of Heart Disease
  262. SARS-CoV-2 Vaccination in India: Considerations of Hesitancy and Bioethics in Global Health
  263. Large Cerebral Infarction in Tuberculous Meningitis: Case Report of an Uncommon Complication
  264. Scrub Typhus Presenting with Hemiparesis: Case Report of a Rare Manifestation
  265. 0.54111/0001/vv16
  266. Adherence to Lockdown and Social-Distancing Policies Amidst COVID-19 Pandemic: A Behavioral and Socio-Economic Perspective from India
  267. Letter to the Editor Regarding “Strategies to Address Projected Challenges Facing Foreign Applicants in the U.S. Neurosurgery Match”
  268. ACUTE FATTY LIVER OF PREGNANCY PRESENTING AS INTRAUTERINE FETAL DEATH, POSTPARTUM HEMORRHAGE AND MULTI-ORGAN FAILURE: NEED FOR A MULTI-DISCIPLINARY, INTENSIVIST-LED MANAGEMENT
  269. Learning high‐value care in developing countries
  270. Why are India’s Best Medical Graduates not Preferring ENT for Postgraduate Training Through NEET-PG?
  271. Abstracts from the International Science Symposium on HIV and Infectious Diseases (ISSHID 2019): Infectious diseases
  272. Scrub Typhus: Case of a Rare Etiology Behind Intracerebral Hemorrhage (204)
  273. Stroke in persons with disability
  274. Postoperative urinary retention: A controlled trial of fixed-dose spinal anesthesia using bupivacaine versus ropivacaine
  275. Transhepatic intraperitoneally migrated biliary stent: A rare finding during laparoscopic cholecystectomy
  276. Training and Delivery of Critical Care Medicine in India: Concerns Revealed by COVID-19 Pandemic
  277. A rare etiology behind isolated lateral rectus palsy: Scrub typhus
  278. Scrub typhus manifesting with intracerebral hemorrhage: Case report and review of literature
  279. Impaled roadside guardrail in the neck: Case of a failed motorcycle stunt
  280. Academic quality of incoming ophthalmology residents in India: Concerns for the future
  281. Bilateral limb gangrene in an HIV patient due to vasculopathy: Managing the dual challenge of psychosocial issues and an uncommon medical condition
  282. Upsurge of chikungunya cases in Uttar Pradesh, India
  283. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators
  284. The US Residency Selection Process After the United States Medical Licensing Examination Step 1 Pass/Fail Change: Overview for Applicants and Educators